论文部分内容阅读
本文评价静脉注射氟卡胺对新发室上性心动过速(SVT)的疗效和安全性。方法:50例SVT持续时间<24小时的病人,其中46例为特发性,另4例由电生理检查所诱发。将病人分为三组:Ⅰ组25例房颤病人,其中18例有心脏病;Ⅱ组15例房室结或房室折返性心动过速病人;Ⅲ组10例房性折返性心动过速伴房室传导阻滞(通常是2∶1)的病人,其中4例有心脏病。将氟卡胺以每分钟15mg的速度静脉注射,直至最大剂量2mg/kg或150mg。治疗后观察45分钟内效果。结果:38例(76%)病人治疗后转为窦律。其中Ⅰ组19例(76%),平均剂量为120
This article evaluates the efficacy and safety of intravenous flecainide in the treatment of new supraventricular tachycardia (SVT). Methods: Fifty patients with SVT lasting less than 24 hours, of whom 46 were idiopathic and the other 4 were induced by electrophysiological examination. The patients were divided into three groups: group Ⅰ 25 patients with atrial fibrillation, of which 18 patients with heart disease; Ⅱ group of 15 patients with atrioventricular node or atrioventricular reentrant tachycardia; Ⅲ group of 10 patients with atrial reentrant tachycardia With atrioventricular block (usually 2: 1) of the patients, of which 4 cases of heart disease. Flecainide was intravenously injected at a rate of 15 mg per minute up to a maximum dose of 2 mg / kg or 150 mg. Observed within 45 minutes after treatment effect. RESULTS: Thirty-eight (76%) patients switched to sinus rhythm after treatment. In group I, 19 cases (76%), the average dose was 120